Silence Therapeutics plc Share Price London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 449M 594M 530M 493M 847M 57.46B 851M 5.94B 2.33B 29.29B 2.23B 2.18B 94B | P/E 2026 * |
-19.3x | P/E 2027 * | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 316M 418M 373M 347M 596M 40.41B 598M 4.18B 1.64B 20.6B 1.57B 1.53B 66.11B | EV / Sales 2026 * |
971x | EV / Sales 2027 * | 314x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 30/11/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 31/01/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 20/06/2018 |
Iain Ross
CHM | Chairman | 72 | 31/12/2003 |
Tim McInerney
BRD | Director/Board Member | 65 | 04/05/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.59% | -5.70% | +39.83% | +82.45% | 70.61B | |
| +3.23% | -10.67% | +4.87% | +55.97% | 51.01B | |
| +1.56% | +1.17% | +5.15% | +33.38% | 48.1B | |
| +0.39% | +0.65% | +28.02% | +30.24% | 42.78B | |
| +0.87% | -8.17% | +298.53% | +645.03% | 40.67B | |
| +1.24% | -1.01% | +5.56% | +105.14% | 40.3B | |
| -2.13% | -1.64% | +7.51% | +50.31% | 30.59B | |
| -0.46% | -1.28% | +31.47% | +19.93% | 28.16B | |
| +5.32% | +0.06% | -7.20% | -11.30% | 24.36B | |
| Average | +0.83% | -2.66% | +45.97% | +112.35% | 41.84B | |
| Weighted average by Cap. | +0.56% | -2.94% | +47.30% | +116.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 325K 430K 384K 357K 614K 41.62M 616K 4.3M 1.69M 21.22M 1.62M 1.58M 68.1M | 876K 1.16M 1.03M 963K 1.65M 112M 1.66M 11.59M 4.54M 57.17M 4.35M 4.26M 183M |
| Net income | -42.18M -55.82M -49.85M -46.37M -79.64M -5.4B -79.99M -558M -219M -2.75B -210M -205M -8.84B | -64.3M -85.09M -75.99M -70.69M -121M -8.23B -122M -851M -333M -4.2B -320M -313M -13.47B |
| Net Debt | -133M -176M -157M -146M -251M -17.05B -252M -1.76B -690M -8.69B -661M -647M -27.89B | -174M -230M -206M -191M -329M -22.29B -330M -2.3B -902M -11.36B -865M -846M -36.47B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
